The least-squares mean difference in the Hammersmith Functional Motor Scale-Expanded change from baseline at 12 months was 1.8 points for those 2 to 12 years receiving apitegromab vs placebo.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Some patients with later-onset spinal muscular atrophy (SMA) type 2 and type 3 had improved motor function when the investigational monoclonal antibody apitegromab was added to their treatment, the ...

Cerebral palsy is a complex neuromotor condition characterised by impairments in movement and posture, often necessitating multidisciplinary rehabilitation approaches. Recent advances have enabled a ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease. An intervention, ...

Old age is accompanied by more than just wrinkles. With age, it typically becomes harder for people to walk, stand up, and move as they used to. This decline in mobility is in part mediated by the ...

Correspondence to Dr Iain Mayank Dutia, The University of Queensland School of Human Movement and Nutrition Sciences, Saint Lucia, QLD 4072, Australia; i.dutia{at}uq.edu.au Objective This study aims ...